Selected Recent
Publications
As of August 4, 2008
Korn EL and Graubard BI. Analysis of Health
Surveys. New
York: John Wiley and Sons,
1999.
Korn EL, Teeter DM and Baumrind S. Using
explicit clinician preferences in nonrandomized study designs. Journal of
Statistical Planning and Inference 96: 67-82, 2001
Korn EL, Arbuck SG, Pluda
JM, Simon R, Kaplan RS, and Christian MC. Clinical trial designs for cytostatic agents: Are new approaches needed? Journal
of Clinical Oncology 19: 265-272, 2001
Graubard BI and Korn EL. Inference
for superpopulation parameters using sample
surveys. Statistical Science 17: 73-96, 2002.
Korn EL, McShane LM, Troendle JF, Rosenwald A, and Simon R. Identifying pre-post
chemotherapy differences in gene expression in breast tumors: A statistical
method appropriate for this aim. British Journal of Cancer 86:
1093-1096, 2002.
Simon RM, Korn EL, McShane LM, Radmacher MD,
Wright GW and Zhao Y. Design and Analysis of DNA Microarray
Investigations. New York:
Springer, 2003
Korn EL, Troendle JF, McShane LM and Simon
R. Controlling the number of false discoveries: application to
high-dimensional genomic data. Journal of Statistical Planning and
Inference 124: 379-398, 2004.
Troendle JF, Korn EL, and McShane LM. An
example of slow convergence of the bootstrap in high dimensions. American
Statistician 58: 25-29, 2004.
Korn EL, Albert PS and McShane LM. Assessing surrogates as trial endpoints
using mixed models (with discussion). Statistics in Medicine 24:163-190, 2005.
Hunsberger
S, Rubinstein LV, Dancey J, and Korn EL. Dose
escalation trial designs based on a molecularly targeted endpoint. Statistics in Medicine 24: 2171-2181,
2005.
Rubinstein LV, Korn EL, Freidlin
B, Hunsberger SA, Ivy P, and Smith MA. Randomized phase 2
design issues and a proposal for phase II screening trials, Journal of Clinical Oncology 23:
7199-7206, 2005.
Korn EL, Hunsberger S, Freidlin B,
Smith MA, and Abrams JS. Preliminary
data release for randomized clinical trials of noninferiority: a new proposal.Journal of Clinical
Oncology 23: 5831-5836, 2005.
Korn EL and Freidlin B. The
likelihood as statistical evidence in multiple comparisons in clinical
trials: no free lunch.Biometrical Journal 48, 1-10, 2006.
Korn EL. Comment: Causal inference in
the medical area. Statistical Science
21, 310-312, 2006.
Korn EL and Freidlin B.A posterior tale. Biometrical
Journal, 49, 346-350, 2007.
Freidlin B and Korn EL. Release of data from an ongoing randomized
clinical trial for sample size adjustment or planning. Statistics
in Medicine 26, 4074-4082, 2007.
Korn EL, Li M-C, McShane LM, and
Simon R. An investigation of two multivariate permutation methods for
controlling the false discovery proportion.
Statistics in Medicine 26,
4428-4440, 2007.
Freidlin B, Korn EL, Hunsberger S,
Gray R, Saxman S, and Zujewski
J. Progression‑free survival in unblinded randomized trials: a
proposal. Journal of Clinical Oncology
25, 2122-2126, 2007.
Dodd LE and Korn EL. The bootstrap
variance of the square of a sample mean. American
Statistician 61, 127-131, 2007.
Freidlin B, Korn EL, George S, and
Gray R. Randomized clinical trial
design for assessing non-inferiority when superiority is expected. Journal of Clinical Oncology 25,
5019-5023, 2007.
Hunsberger S,
Graubard BI, and Korn EL. Testing logistic regression
coefficients with clustered data and few positive outcomes.Statistics
in Medicine 27, 1305-1324, 2008.
Dodd LE and Korn EL. Lack of generalizability of sensitivity and specificity with
treatment effects. Statistics in Medicine 27, 1734-1744,
2008.
Korn EL, Liu PY, Lee SJ, Chapman JW, Niedzwiecki
D,Suman VJ, Moon J, Sondak VK, Atkins MB,
Eisenhauer EA, Parulekar W, Markovic SN, Saxman S,
and Kirkwood JM. Meta-Analysis of
Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma:
Determining Progression-Free and Overall Survival Benchmarks for Future Phase
II Trials. Journal of Clinical Oncology 26, 527-534, 2008. ( Obtain trial-level melanoma data here )
Korn EL and Friedlin
B. A note on controlling the number of false positives.Biometrics
64, 227-231, 2008.
Freidlin B, Korn EL, Gray R, and
Martin A. Multi-arm clinical trials of
new agents: some design considerations.
Clinical Cancer Research 14,
4368-4371, 2008.
Dodd LE, Korn EL, Freidlin B, Jaffe
CC, Rubinstein LV, Dancey J, and Mooney MM. Blinded
independent central review of progression‑free survival in phase III
clinical trials: important design element or unnecessary expense? Journal of Clinical Oncology 22,
3791-3796, 2008.
Lusa L, Korn EL, and McShane LM (in
press) A class comparison method with filtering enhanced variables selection
for high‑dimensional data sets. Statistics
in Medicine.
Freidlin B and Korn EL (in press).
Monitoring for lack of benefit: a critical component of a randomized clinical
trial. Journal of Clinical Oncology.
brb@linus.nci.nih.gov